drug eruptions

Summary

Summary: Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.

Top Publications

  1. ncbi Differential diagnosis of severe cutaneous drug eruptions
    Nicolas Bachot
    Department of Dermatology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Am J Clin Dermatol 4:561-72. 2003
  2. ncbi Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia
    Yoko Kano
    Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
    Arch Dermatol 140:183-8. 2004
  3. ncbi Idiosyncratic adverse reactions to antiepileptic drugs
    Gaetano Zaccara
    Neurology Unit, ASL 10, Firenze, Italy
    Epilepsia 48:1223-44. 2007
  4. ncbi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
    Mario E Lacouture
    Northwestern University, Chicago, IL, USA
    J Clin Oncol 28:1351-7. 2010
  5. ncbi Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
    Celeste B L Man
    Division of Neurology, Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
    Epilepsia 48:1015-8. 2007
  6. ncbi Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans
    Sae Hoon Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
    Epilepsy Res 97:190-7. 2011
  7. ncbi HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions
    Hiroko Ikeda
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
    Epilepsia 51:297-300. 2010
  8. ncbi Drug eruptions in the elderly
    Sueli Coelho da Silva Carneiro
    Sector of Dermatology and Post Graduation Course in Dermatology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rua Farme de Amoedo 140 601, 22420 020 Rio de Janeiro, Brazil
    Clin Dermatol 29:43-8. 2011
  9. ncbi Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population
    Fa Yun Hu
    Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China
    Seizure 20:160-2. 2011
  10. ncbi Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas
    N Rajan
    Clin Exp Dermatol 31:140-1. 2006

Research Grants

Detail Information

Publications238 found, 100 shown here

  1. ncbi Differential diagnosis of severe cutaneous drug eruptions
    Nicolas Bachot
    Department of Dermatology, Hopital Henri Mondor, Universite Paris XII, Creteil, France
    Am J Clin Dermatol 4:561-72. 2003
    ..They are the more severe drug eruptions, with a mortality around 30% for TEN...
  2. ncbi Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia
    Yoko Kano
    Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
    Arch Dermatol 140:183-8. 2004
    ..The identification of predisposing factors is clearly needed to predict the incidence and outcome of AHS; attention has recently been focused on reactivation of human herpesvirus 6 (HHV-6)...
  3. ncbi Idiosyncratic adverse reactions to antiepileptic drugs
    Gaetano Zaccara
    Neurology Unit, ASL 10, Firenze, Italy
    Epilepsia 48:1223-44. 2007
    ..Serious consequences of idiosyncratic reactions can be minimized by knowledge of risk factors, avoidance of specific AEDs in subpopulations at risk, cautious dose titration, and careful monitoring of clinical response...
  4. ncbi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
    Mario E Lacouture
    Northwestern University, Chicago, IL, USA
    J Clin Oncol 28:1351-7. 2010
    ..This is the first study designed to examine differences between pre-emptive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhibitor...
  5. ncbi Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
    Celeste B L Man
    Division of Neurology, Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
    Epilepsia 48:1015-8. 2007
    ..Identification of genetic polymorphisms predisposing to development of AED-induced SCR offers the possibility of avoiding these high-risk drugs in genetically susceptible individuals...
  6. ncbi Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans
    Sae Hoon Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
    Epilepsy Res 97:190-7. 2011
    ..This study investigated the association between the HLA class I genotype and carbamazepine-induced severe cutaneous adverse reaction (SCAR) in Koreans...
  7. ncbi HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions
    Hiroko Ikeda
    National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
    Epilepsia 51:297-300. 2010
    ..These data may suggest that HLA-B*5901 is one of the candidate markers for CBZ-induced SJS in Japanese...
  8. ncbi Drug eruptions in the elderly
    Sueli Coelho da Silva Carneiro
    Sector of Dermatology and Post Graduation Course in Dermatology, University Hospital and School of Medicine, Federal University of Rio de Janeiro, Rua Farme de Amoedo 140 601, 22420 020 Rio de Janeiro, Brazil
    Clin Dermatol 29:43-8. 2011
    ..The potential benefits of appropriately prescribed medications are unquestionable, but the possibility of an adverse reaction must be recognized and prevented in older people so they can have a better quality of life...
  9. ncbi Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population
    Fa Yun Hu
    Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China
    Seizure 20:160-2. 2011
    ..In the present study, we conducted a pilot study to detect a possible association of oxcarbazepine (OXC)-induced MPE with HLA-B*1502 allele in Chinese Han population...
  10. ncbi Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas
    N Rajan
    Clin Exp Dermatol 31:140-1. 2006
  11. ncbi Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions
    Ai Young Lee
    Department of Dermatology, Eulji Hospital, Eulji University School of Medicine, 280 1 Hagye 1 dong, Nowon Gu, 139 711 Seoul, South Korea
    Eur J Clin Pharmacol 60:155-9. 2004
    ..Genetic polymorphisms leading to altered metabolic processes of cytochrome P(450) (CYP) 2C9, a main metabolic enzyme for DPH, may be the pathological mechanism for certain cases of DPH-induced CADRs...
  12. ncbi Severe adverse cutaneous drug eruptions: epidemiological and clinical features
    Ines Zaraa
    Dermatology Department, La Rabta Hospital, Jabbari, Bab Saadoun 1007, Tunis, Tunisia
    Int J Dermatol 50:877-80. 2011
    ..Adverse cutaneous drug reactions (ACDR) are common, and some can be lethal. The aim of our study was to discuss the epidemiological and clinical features of severe ACDR...
  13. ncbi Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients
    Sue Mian Then
    UKM Medical Molecular Biology Institute UMBI, Universiti Kebangsaan Malaysia UKM, Kuala Lumpur, Malaysia
    Asian Pac J Allergy Immunol 29:290-3. 2011
    ..In conclusion, this study confirmed the association of HLA-B*1502 with CBZ-SJS among Malaysian epilepsy patients, however there might be other genes that could be responsible for the CBZ-induced rash...
  14. ncbi Cutaneous reaction to drugs used for erectile dysfunction: case report and review of the literature
    Renee A Beach
    Department of Medicine, McMaster University, Hamilton, ON
    J Cutan Med Surg 10:128-30. 2006
    ..These drugs, phosphodiesterase 5 (PDE5) inhibitors, help men with ED obtain and sustain an erection, improving both sexual function and sexual performance satisfaction. However, these drugs contain side effects...
  15. ncbi Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review
    Aikaterini Evaggelia Moustou
    1st Department of Dermatology, Andreas Sygros Hospital, University of Athens Medical School, Athens, Greece
    J Am Acad Dermatol 61:486-504. 2009
    ..Anti-tumor necrosis factor (anti-TNF) biologic agents have been associated with a number of adverse events...
  16. ncbi Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management
    A Neil Crowson
    University of Oklahoma and Regional Medical Laboratories, Tulsa, Oklahoma, USA
    Am J Clin Dermatol 4:407-28. 2003
    Cutaneous drug eruptions are among the most common adverse reactions to drug therapy. The etiology may reflect immunologic or nonimmunologic mechanisms, the former encompassing all of the classic Gell and Combs immune mechanisms...
  17. ncbi Exanthematous drug eruption due to valsartan
    Gunseli Ozturk
    Department of Dermatology and Venerology, Ege University Medical Faculty, Izmir, Turkey
    Cutan Ocul Toxicol 31:335-7. 2012
    ..The well-known adverse effects of valsartan are dizziness, headache and cough. Valsartan-related cutaneous side effects have been reported previously in a limited number of case reports...
  18. ncbi Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions
    K Hirahara
    Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
    Clin Exp Dermatol 35:863-8. 2010
    ....
  19. ncbi Fixed drug eruptions due to cotrimoxazole
    M A Miah
    Department of Dermatology and Venereology, Mymensingh Medical College and Hospital, Mymensingh, Bangladesh
    Mymensingh Med J 17:S1-5. 2008
    ..44% cases. Sites of involvement in cases of FDE due to cotrimoxazole (n=36) were as follows: lips 58.33%, genitalia 33.33%, oral 13.89%, trunk 38.89%, limbs 55.56%, hands 16.67%, feet 19.44%, face 19.44% and conjunctiva 2.78%...
  20. ncbi Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles
    Na He
    Institute of Neuroscience and The Second Affiliated Hospital of GuangZhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and The Ministry of Education of China, Guangzhou 510260, China
    Seizure 21:614-8. 2012
    ..Additionally, these reactions are thought to be associated with HLA-B*1502. This study aims to investigate the incidence, features and risk factors of OXC-cADRs, and to explore their relation to HLA-B alleles in Southern Han Chinese...
  21. ncbi Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature
    Katharina Lorentz
    Department of Dermatology, University Clinic of Mannheim, Medical School of Mannheim at the University of Heidelberg, Germany
    J Dtsch Dermatol Ges 6:823-7, 823-8. 2008
    ..In all cases terbinafine-induced SCLE resolved after discontinuation of the triggering agent. Systemic treatment with anti-malarials and/or corticosteroids does not appear to be mandatory...
  22. ncbi [Drug-induced lupus erythematosus tumidus during treatment with adalimumab]
    S Sohl
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Leipzig AoR, Philipp Rosenthal Strasse 23 25, 04103 Leipzig
    Hautarzt 60:826-9. 2009
    ..We report on a patient with rheumatoid arthritis, who developed anti-histone antibodies and lupus tumidus after eight months on adalimumab therapy...
  23. ncbi Patch testing in fixed drug eruptions--a 20-year review
    Pedro Andrade
    Department of Dermatology and Venereology, Coimbra University Hospital, 3000 075 Coimbra, Portugal
    Contact Dermatitis 65:195-201. 2011
    ..The fixed drug eruption is a common adverse drug reaction. Clear identification of the culprit drug is not always possible in the clinical setting, and oral rechallenge may induce new lesions or severe reactions...
  24. ncbi Clinical and laboratory assays in the diagnosis of cutaneous adverse drug reactions
    Ilan Goldberg
    Isr Med Assoc J 6:50-1. 2004
  25. ncbi Pathogenesis of drug-induced exanthems
    W Pichler
    Division of Allergology, Clinic for Rheumatology and Clinical Immunology Allergology, Inselspital, University of Bern, Switzerland
    Allergy 57:884-93. 2002
  26. ncbi Carbamazepine-induced acute granulomatous interstitial nephritis
    J Hegarty
    Department of Renal Medicine, Hope Hospital, Salford, UK
    Clin Nephrol 57:310-3. 2002
    ..Percutaneous renal biopsy revealed acute granulomatous interstitial nephritis, which responded successfully to high-dose oral steroid therapy...
  27. ncbi Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update
    S Tas
    Department of Dermatology, Erasme University Hospital, Brussels, Belgium
    Dermatology 206:353-6. 2003
    ..In the absence of a well-established therapy, primary and secondary prevention have a key role in the management of DRESS syndrome...
  28. ncbi Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh, India
    V K Sharma
    Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India
    J Postgrad Med 47:95-9. 2001
    ..To study the different clinical spectrum of cutaneous adverse drug reactions (ADR) and to determine the causative drugs...
  29. ncbi The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug
    Yoko Kano
    Department of Dermatology, Kyorin University School of Medicine, 6 20 2 Shinkawa Mitaka, Tokyo 181 8611, Japan
    Immunol Allergy Clin North Am 29:481-501. 2009
    ..A better understanding of the interplay in the development of DIHS/DRESS has implications for safer and more efficient treatment of this syndrome...
  30. ncbi Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs
    T D Fernandez
    Research Laboratory for Allergic Diseases, Carlos Haya Hospital Fundacion IMABIS, Malaga, Spain
    Allergy 63:712-9. 2008
    ..We assessed the role of cytokines and chemokines and their receptors in the pathogenesis of MPE...
  31. ncbi Life-threatening acute adverse cutaneous drug reactions
    Ronni Wolf
    Dermatology Unit, Kaplan Medical Center, 76100 Rechovot, Israel
    Clin Dermatol 23:171-81. 2005
    ..Therefore, dermatologists should be familiar with these conditions and be prepared to handle them adequately...
  32. ncbi Clinical pattern of cutaneous drug eruption among children and adolescents in north India
    V K Sharma
    Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    Pediatr Dermatol 12:178-83. 1995
    Various types of cutaneous drug eruptions and the incriminating drugs were analyzed in 50 children and adolescents up to 18 years of age (34 or 65% boys, 16 or 32% girls)...
  33. ncbi Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod
    P A Fanti
    Int J Dermatol 45:1464-5. 2006
  34. ncbi Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae
    Lynne I Wagner
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Northwestern University, Feinberg Medical School, Chicago, IL 60611, USA
    Oncology (Williston Park) 21:34-6. 2007
    ..Cognitive behavioral strategies may also be useful in helping patients manage anxiety and depression associated with any changes in their social function caused by skin rash, as well as distress associated with having a cancer diagnosis...
  35. ncbi Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions
    Sima Halevy
    Department of Dermatology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    J Am Acad Dermatol 52:254-61. 2005
    ..Drug-specific T cells are involved in the pathogenesis of cutaneous adverse drug reactions (CADRs)...
  36. ncbi Drug-induced lupus: an update
    S Vasoo
    Division of Rheumatology, Department of Medicine, National University Hospital, Singapore
    Lupus 15:757-61. 2006
    ..This review discusses the clinical presentation, diagnosis of DILE as well as provides an update on postulated pathogenic mechanisms and an overview of implicated drugs...
  37. ncbi Drug-induced lupus erythematosus
    Dimitar Antonov
    Department of Dermatology and Venereology, Sofia Faculty of Medicine, Sofia, Bulgaria
    Clin Dermatol 22:157-66. 2004
    ..This review discusses the general issues in DILE, such as pathogenic mechanisms, clinical forms, and diagnostic criteria, and provides more detailed information for some of the implicated drugs: minocycline, statins, terbinafine, etc...
  38. ncbi Cutaneous adverse drug reactions: a 9-year study from a South Indian Hospital
    M Sushma
    Department of Pharmacology, St John s Medical College, Bangalore, India
    Pharmacoepidemiol Drug Saf 14:567-70. 2005
    ....
  39. ncbi Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells
    Tetsuo Shiohara
    Kyorin University School of Medicine, 6 20 2, Shinkawa, Mitaka, Tokyo, Japan
    Eur J Dermatol 17:201-8. 2007
    ..In this review, we ask how they arise and how they cause epidermal injuries, which present with a wide spectrum of clinical manifestations and are often mistaken as signs of other skin disease...
  40. ncbi Cross-sensitivity of skin rashes with antiepileptic drug use
    L J Hirsch
    Associate Clinical Comprehensive Epilepsy Center, Columbia University, Neurological Institute, New York, NY 10032, USA
    Neurology 71:1527-34. 2008
    ..To determine rates of cross-sensitivity of rash among commonly used antiepileptic drugs (AEDs) in patients with epilepsy...
  41. ncbi Induction of hypersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug
    B D Klassen
    Division of Neurology, Dalhousie University, Halifax, Nova Scotia, Canada
    Epilepsia 42:433-5. 2001
    ..This is distinct from simple cross-reactivity between one or more drugs. Such induction of hypersensitivity with AEDs has not been previously described...
  42. pmc Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    Bruno Vincenzi
    Department of Surgical and Oncological Sciences, Section of Medical Oncology Università di Palermo, Palermo, Italy, Via del Vespro 127, 90127 Palermo, Italy
    Oncologist 15:85-92. 2010
    ..This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients...
  43. ncbi Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome
    Ryo Takahashi
    Division of Flow Cytometry, Kyorin University Graduate School of Medicine, Mitaka, Tokyo, Japan
    J Immunol 182:8071-9. 2009
    ..necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS) represent two ends of a spectrum of severe drug eruptions: DIHS is unique in that severe epidermal damage seen in TEN is absent, sequential reactivations of ..
  44. ncbi Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy
    Tetsuo Shiohara
    Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
    Allergol Int 59:333-43. 2010
    ..with a broad-spectrum of immunosuppressive therapy-related opportunistic infectious diseases and severe drug eruptions complicated by viral reactivations...
  45. ncbi Comparison and predictors of rash associated with 15 antiepileptic drugs
    H Arif
    Comprehensive Epilepsy Center, Department of Neurology, Columbia University, New York, NY 10032, USA
    Neurology 68:1701-9. 2007
    ..To determine predictors and relative incidence of antiepileptic drug (AED)-related rash in patients taking all common AEDs...
  46. ncbi Fixed drug eruptions. Incidence, recognition, and avoidance
    A Y Lee
    Department of Dermatology, Eulji Hospital College of Medicine, Seoul, South Korea
    Am J Clin Dermatol 1:277-85. 2000
    b>Drug eruptions often have nonspecific clinical findings, and the evaluation of the probability of an eruption being a drug-induced event is difficult...
  47. ncbi Cutaneous drug eruptions: a 5-year experience
    Deborah Gerson
    The Arkadi M Rywlin, M D Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center of Greater Miami, Miami, Florida, USA
    J Am Acad Dermatol 59:995-9. 2008
    The diversity of cutaneous drug eruptions encompasses many clinicopathologic entities.
  48. ncbi Clinical study of cutaneous drug eruptions in 200 patients
    M Patel Raksha
    Department of Skin and V D, Medical College, Vadodara, India
    Indian J Dermatol Venereol Leprol 74:80. 2008
    ..The youngest was 1 year old and the oldest was 80 years old. Period of development of lesion after intake of drug varied from 1 day to 45 days. Cotrimoxazole was the commonest drug, in 26 cases; followed by Ibuprofen in 20 cases...
  49. ncbi Adverse cutaneous drug eruptions and HIV: a clinician's global perspective
    Gail Todd
    Division of Dermatology, University of Cape Town, Faculty of Health Sciences, Nard 623, Cape Town, South Africa
    Dermatol Clin 24:459-72, vi. 2006
    ..When no effective alternate therapy is available, drug rechallenge in HIV-infected patients can be attempted with little morbidity or mortality if done according to rationalized protocols...
  50. doi Fixed drug eruption caused by itraconazole: Reactivity and cross reactivity
    Rajan Gupta
    J Am Acad Dermatol 58:521-2. 2008
  51. ncbi T cell involvement in cutaneous drug eruptions
    Y Hari
    Allergy Division of the Clinic for Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switzerland
    Clin Exp Allergy 31:1398-408. 2001
    ..A predominant CD8(+) T cell activation leads to more severe (bullous) skin symptoms or liver involvement, while predominant activation of CD4(+) cells elicits mainly maculo-papular reactions...
  52. ncbi Chemotherapeutic agents and the skin: An update
    Noushin Heidary
    Ronald O Perelman Department of Dermatology, New York University, New York, USA
    J Am Acad Dermatol 58:545-70. 2008
    ..Particular emphasis is placed on the novel signal transduction inhibitors as well as on newer literature pertaining to previously described reactions...
  53. ncbi Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients
    A T Vila
    Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Br J Dermatol 153:417-23. 2005
    ..Anakinra, a recombinant human form of interleukin-1 receptor antagonist, is used to treat patients with active rheumatoid arthritis (RA)...
  54. ncbi Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses
    Tetsuo Shiohara
    Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
    Allergol Int 55:1-8. 2006
    ..This review includes discussion of the pathomechanism, the clinical symptoms, laboratory findings, pathological findings and therapy...
  55. ncbi Common side effects of anti-EGFR therapy: acneform rash
    Rebecca Sipples
    Yale Comprehensive Cancer Center, 333 Cedar Street, New Haven, CT 06520, USA
    Semin Oncol Nurs 22:28-34. 2006
    ..To review the general toxicity profile of EGFR-targeted therapies and the management of the most common side effect, skin toxicity...
  56. ncbi Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema
    Julia Valencak
    Department of Dermatology, Division of General Dermatology, University of Vienna, Vienna, Austria
    Int J Dermatol 43:51-4. 2004
  57. ncbi Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor
    G Gencoglan
    Department of Dermatology, Medical Faculty of Afyon Kocatepe University, Afyon, Turkey
    Skin Pharmacol Physiol 20:260-2. 2007
    ..Cetuximab is a member of a new family of antineoplastic agents that inhibit the epidermal growth factor receptor (EGF-R), and which are increasingly being used in the treatment of solid tumors...
  58. pmc Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome
    Cheol Woo Kim
    Department of Internal Medicine, Inha University College of Medicine, Jung Gu, Incheon, Korea
    J Korean Med Sci 21:768-72. 2006
    ....
  59. ncbi Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome
    Yusuke Asano
    Department of Dermatology, Kyorin University School of Medicine, 6 20 2 Shinkawa Mitaka, Tokyo 181 8611, Japan
    Arch Dermatol 145:1030-6. 2009
    ..Cutaneous lesions, albeit rare, occur as late systemic manifestations of CMV infections and are usually fatal...
  60. ncbi Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions
    A Barbaud
    Dermatology Department, Hopital Fournier, 54000 Nancy, France
    Contact Dermatitis 45:321-8. 2001
    ..The results of drug skin tests also depend on the clinical features of the CADR. The use of appropriate control patients is necessary to avoid false-positive results...
  61. ncbi Clinical research of EGFR inhibitors and related dermatologic toxicities
    Roman Perez-Soler
    Division of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    Oncology (Williston Park) 21:10-6. 2007
    ..Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials...
  62. ncbi Insulin-induced drug eruptions and reliability of skin tests
    Al Young Lee
    Department of Dermatology, Eulji Hospital, Eulji University School of Medicine, Seoul, South Korea
    Acta Derm Venereol 82:114-7. 2002
    ..Allergic reactions to protamine sulfate are common and should not be ignored. This study shows a good correlation between clinical manifestations and skin test reactions for insulin allergy...
  63. ncbi [Retrospective analysis of adverse cutaneous drug reactions in patients hospitalized in Department of Dermatology and Venereology of Pomeranian Medical University in 1996-2006]
    Anna Kacalak-Rzepka
    Katedra i Klinika Chorób Skórnych i Wenerycznych Pomorskiej Akademii Medycznej w Szczecinie al Powstańców Wlkp 72, 70 111 Szczecin
    Ann Acad Med Stetin 54:52-8. 2008
    ....
  64. ncbi Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus
    Paul B Hillesheim
    Department of Pathology and Laboratory Medicine, University of Louisville, 530 S Jackson St, Louisville, KY 40202, USA
    Arch Dermatol 148:190-3. 2012
    ..To investigate whether tissue eosinophilia is a differentiating histopathologic feature of drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) compared with non-DI-SCLE...
  65. ncbi Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
    A F S Galimont-Collen
    Department of Dermatology, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Cancer 43:845-51. 2007
    ..Informing the patient and management of these side-effects is very important to reduce discomfort and as such to increase compliance to therapy...
  66. ncbi Fixed drug eruptions: a case report and review of the literature
    Sarah B Gendernalik
    Naval Air Station Whidbey Island, Oak Harbor, Washington, USA
    Cutis 84:215-9. 2009
    Fixed drug eruptions (FDEs) have been described since 1889 with continually evolving documentation of implicated agents and clinical presentations. We report a case of FDE as a reaction to naproxen sodium in a 27-year-old woman...
  67. ncbi A three-year-analysis of fixed drug eruptions in hospital settings in France
    Nesrine Brahimi
    Department of Dermatology, Bichat Hospital, APHP, 46 rue Henri Huchard, 75877 Paris, France
    Eur J Dermatol 20:461-4. 2010
    ..The sex-dependent distribution could help our understanding of the pathophysiology of fixed drug eruption...
  68. ncbi In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion
    B Sachs
    Department of Dermatology and Allergology, University Hospitals, Rheinisch Westfälische Technische Hochschule Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
    Br J Dermatol 144:316-20. 2001
    ..We report a woman who developed a generalized exanthem 1 day after receiving chlorazepate and four other drugs related to anaesthesia for surgery of the larynx. Patch tests pointed to chlorazepate as the culprit drug for the skin rash...
  69. ncbi ACE-inhibitor-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and Lupus erythematosus tumidus
    Carmelo Schepis
    Dermatology 208:354-5. 2004
  70. ncbi Toward evidence-based management of the dermatologic effects of EGFR inhibitors
    Patricia LoRusso
    Phase I Clinical Trial Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
    Oncology (Williston Park) 23:186-94. 2009
    ..These reports represent the first step toward an evidence-based approach to the prevention and management of these important effects...
  71. ncbi Drug eruptions and other adverse drug effects in aged skin
    John R Sullivan
    Drug Safety Clinic, Department of Medicine, University of Toronto Medical School, Ontario, Canada
    Clin Geriatr Med 18:21-42. 2002
    ....
  72. ncbi Clinical study of cutaneous drug eruptions in 200 patients
    Raksha M Patel
    Department of Skin and V D, Medical College, Vadodara, Gujarat, India
    Indian J Dermatol Venereol Leprol 74:430. 2008
    ..Cutaneous drug reactions are the most common adverse reactions attributed to drugs. Any skin disorder can be imitated, induced or aggravated by drugs...
  73. ncbi Cutaneous reactions to drugs in children
    Alissa R Segal
    Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, 179 Longwood Ave, Boston, MA 02115 5896, USA
    Pediatrics 120:e1082-96. 2007
    ..The purpose of this review is to discuss a reasonable approach to recognition and initial management of cutaneous adverse drug reactions in children...
  74. ncbi New advances in severe adverse drug reactions
    J Revuz
    Department of Dermatology, Henri Mondor Hospital, Creteil, France
    Dermatol Clin 19:697-709, ix. 2001
    ..Usually the clinical pattern is well known and has been described in association with other drugs; new entities, however, are described frequently. This article reviews several of them...
  75. ncbi [Severe cutaneous drug reactions to celecoxib (Celebrex)]
    S Marques
    Clinique Dermatologique, CHU Hotel Dieu, Nantes
    Ann Dermatol Venereol 130:1051-5. 2003
    ..Adverse reactions reported are usually benign, such as maculopapular exanthema. However, recently severe toxiderma have started to appear. We report two patients who developed a sever celecoxib drug skin reaction...
  76. ncbi Rash from antiepileptic drugs: influence by gender, age, and learning disability
    Silje Alvestad
    Department of Neuroscience, Norwegian University of Science and Technology NTNU, Trondheim, Norway
    Epilepsia 48:1360-5. 2007
    ..We wanted to study the incidence of skin reactions of current AEDs and to explore their relation to clinical parameters such as gender, age, and learning disability...
  77. ncbi Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer
    M Wasif Saif
    Division of Medical Onclogy, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 7:144-8. 2008
    ..To our knowledge, this case report is the second report of possible correlation between rash and a positive drug response associated with bevacizumab and warrants further investigation of similar observation...
  78. ncbi DRESS syndrome associated with carbamazepine and phenytoin
    Jean Pierre Allam
    Department of Dermatology, Friedrich Wilhelms University, Sigmund Freud Str 25 D 53105 Bonn, Germany
    Eur J Dermatol 14:339-42. 2004
    ..ECP blood levels may represent a sufficient parameter to monitor the development of DRESS syndrome...
  79. doi Mercury-induced acute generalized exanthematous pustulosis misdiagnosed as a drug-related case
    Hichem Belhadjali
    Department of Dermatology, Fattouma Bourguiba Hospital, Monastir 500, Tunisia
    Contact Dermatitis 59:52-4. 2008
  80. ncbi [Medical emergencies following dermatological injections and infusions]
    D Dill-Müller
    Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum des Saarlandes, Homburg Saar
    Hautarzt 57:195-201. 2006
    ..5%. Every oncologic department should have an understanding of necrotic risk of the various agents and an emergency kit with instructions for immediate steps, also including agent-specific antidotes as available...
  81. ncbi Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period
    Kaija Lammintausta
    Department of Dermatology, Turku University Central Hospital, Finland
    Acta Derm Venereol 85:491-6. 2005
    ..Out-patient protocol can be used in most cases...
  82. ncbi [Fluindione-induced acute generalised exanthematous pustulosis confirmed by patch testing]
    M Chtioui
    Service de Dermatologie, Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, 9, avenue Charles de Gaulle, 92100 Boulogne Billancourt, France
    Ann Dermatol Venereol 135:295-8. 2008
    ..Although fluindione is very widely prescribed in France, few cases of cutaneous drug reactions have been reported. Below we describe a case of acute generalised exanthematous pustulosis due to fluindione as confirmed by patch-testing...
  83. ncbi [Acute localized exanthematous pustulosis (ALEP)]
    Birte Prange
    Hautklinik, Heinrich Heine Universitat Dusseldorf, Germany
    J Dtsch Dermatol Ges 3:210-2. 2005
    ..We report on a female patient who according to the criteria of AGEP was diagnosed as having acute localized exanthematic pustulosis (ALEP) on the face...
  84. ncbi Delayed hypersensitivity reactions to corticosteroids
    S Cadinha
    Serviço de Imunoalergologia, Hospital Sao Joao, Porto, Portugal
    Allergol Immunopathol (Madr) 33:329-32. 2005
    ..However, more and more cases of hypersensitivity reactions to CS have been described. Reports of delayed allergic reactions to CS in patients with asthma or allergic rhinitis are scarce...
  85. ncbi Acute generalized exanthematous pustulosis due to tetrazepam
    E Thomas
    Allergy Department, Hospital La Paz, Madrid, Spain
    J Investig Allergol Clin Immunol 18:119-22. 2008
    ..These results support previous data suggesting an important role for IL-8 and drug-specific T cells in the pathogenesis ofAGEP and imply that the reaction was specific to tetrazepam with no cross-reactivity to other benzodiazepines...
  86. ncbi Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test
    P Hausermann
    Department of Dermatology, University Hospital Basel, Switzerland
    Dermatology 211:277-80. 2005
    ..Furthermore, we highlight in this particular case the challenging differentiation from bullous drug eruption...
  87. ncbi Drug hypersensitivity reactions: from clinical manifestations to an allergologic diagnosis
    S Bach
    Allergy Unit, Department of Dermatology, University Hospital Basel, Switzerland
    Eur Ann Allergy Clin Immunol 37:213-8. 2005
  88. ncbi Case of acute generalized exanthematous pustulosis caused by ampicillin/cloxacillin sodium in a pregnant woman
    Yuka Matsumoto
    Department of Dermatology, Tokyo Medical University, Tokyo, Japan
    J Dermatol 35:362-4. 2008
    ..To our knowledge, this is only the second case ever reported in the Japanese language published work of AGEP induced by ABPC/MCIPC...
  89. ncbi [Cutaneous drug reactions]
    Claus Lützow-Holm
    Hudavdelingen, Ulleval universitetssykehus, 0407 Oslo
    Tidsskr Nor Laegeforen 125:2483-7. 2005
    ..Adverse cutaneous reactions to drugs are frequent in general practice. This article is a review of current knowledge of the pathogenesis, differential diagnosis and practical management of this wide spectrum of cutaneous manifestations...
  90. ncbi [Disseminated erythematous maculae with central bullae formation. Generalized fixed drug exanthema]
    Stefan Werner Schneider
    Klinik und Poliklinik für Hautkrankheiten, Universitatsklinikum Munster
    J Dtsch Dermatol Ges 2:143-6. 2004
  91. ncbi Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test
    Sylvia H Kardaun
    Department of Dermatology, University Medical Center Groningen, University of Groningen, The Netherlands
    J Am Acad Dermatol 55:S21-3. 2006
    ..Best known are urticaria, erythema, and pruritus; sometimes pseudoallergic anaphylactoid reactions, and blisters are reported...
  92. ncbi [Adverse effects and safety of antimicrobial agents--allergy]
    Zenro Ikezawa
    Department of Dermatology, Yokohama City University Graduate School of Medicine
    Nihon Rinsho 65:578-86. 2007
  93. ncbi [The allergic and other side effects of non-steroid antiinflammatory drugs and gold salts]
    Lajos Attila Réthy
    Magyar Tudományos Akademia Pécsi Tudományegyetem, Klinikai Genetikai Munkacsoport, Pecs
    Orv Hetil 145:1943-9. 2004
    ..Next to salicylates the most frequent side effects were caused by pyrazolon derivates. Urticaria and angioedema were the most frequently observed symptoms on the skin--our observations are in accordance with other publications...
  94. ncbi DRESS syndrome from cefadroxil confirmed by positive patch test
    M Hernanto
    Department of Dermatovenereology, Faculty of Medicine, Gadjah Mada University, J1, Kesehatan No 1, Sekip Yogyakarta 55281, Indonesia
    Allergy 62:1216-7. 2007
  95. ncbi Drug-induced linear immunoglobulin A bullous dermatosis mimicking Stevens-Johnson syndrome: a case report
    Julie E Cummings
    University of Texas Medical Branch, Galveston TX 77550, USA
    Cutis 79:203-7. 2007
    ..The patient's bullous eruption resolved with discontinuation of the offending medications and treatment with prednisone and pentoxifylline...
  96. ncbi [Allergy to antibiotics]
    A Hamzaoui
    Pavillon B, Hôpital A Mami de Pneumologie, Ariana, Tunisie
    Rev Mal Respir 23:10S70-10S72. 2006
  97. ncbi [Co-sensitization to drugs belonging to different chemical classes during the same episode of cutaneous adverse drug reaction: two cases]
    P Dellestable
    Service de Dermatologie, Hopital Fournier, Nancy
    Ann Dermatol Venereol 134:655-8. 2007
    ....
  98. ncbi Polysensitivity in fixed drug eruption due to a novel drug combination-independent lesions due to piroxicam and cotrimoxazole
    Esen Ozkaya
    Eur J Dermatol 16:591-2. 2006
  99. ncbi Prevalence of drug allergy in an out-patient population
    A G Palma-Carlos
    Clinical Allergy Immunology Center, Lisbon, Portugal
    Eur Ann Allergy Clin Immunol 38:142-5. 2006
    ..Clinical history and skin tests are sufficient to diagnose most cases of drug allergy...
  100. ncbi Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia
    Yoshihiro Kuwano
    Int J Dermatol 45:1249-51. 2006
  101. doi Allergological approach to drug hypersensitivity reactions
    Bernhard Przybilla
    Klinik und Poliklinik fur Dermatologie und Allergologie, Ludwig Maximilians Universität Frauenlobstr 9 1180337 Munich, Germany
    J Dtsch Dermatol Ges 6:240-3. 2008

Research Grants38

  1. T-CELL MECHANISMS OF PATHOLOGY IN DTH & DRUG ERUPTIONS
    Richard Kalish; Fiscal Year: 1992
    ..cutaneous pathology in allergic contact dermatitis to urushiol (Toxicodendron radicans, "poison ivy") and in drug eruptions. These conditions were chosen because the relevant antigen is known, lending them amenable to analysis...
  2. MECHANISMS OF CUTANEOUS INJURY IN LUPUS ERYTHEMATOSUS
    Richard Sontheimer; Fiscal Year: 1991
    ..These studies might also yield insight into the pathogenesis of other related inflammatory skin diseases such as lichen planus, dermatomyositis and lichenoid drug eruptions.
  3. INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER
    Roman Perez Soler; Fiscal Year: 2004
    ..Four such candidates have already been identified. It is anticipated that a total of ten young clinical investigators will be mentored during a five-year period. ..
  4. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2003
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  5. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2010
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  6. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2004
    ..abstract_text> ..
  7. Long-Circulating Liposomal Camptothecins CAP and EAP
    Roman Perez Soler; Fiscal Year: 2003
    ..Ultimately, we will seek formulation(s) that display optimized drug retention and in vivo and in vitro performance. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  8. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  9. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  10. MIDCAREER INVESTIGATOR AWARD IN NEURO-AIDS RESEARCH
    David Simpson; Fiscal Year: 2005
    ..The Neuro-Adherence Program will assess the affect of neurological disease on patients' adherence to medical regimens, and the impact of education and support groups on adherence. ..
  11. Nicotine Replacement Treatment for Pregnant Smokers
    Cheryl Oncken; Fiscal Year: 2006
    ..The odds of cigarette abstinence will be increased primarily in subjects who smoke at least 15 cigarettes per day...
  12. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  13. Dendritic Cell Vaccination During Lymphoid Reconstitution
    Jeffrey Weber; Fiscal Year: 2008
    ..Toxicity as well as clinical response will be secondary endpoints. The cohort with the optimal level of immune response will be taken forward in future studies. ..
  14. Nitogen reduction and xenobiotic response
    Lauren A Trepanier; Fiscal Year: 2010
    ..The ultimate goal of these studies is to find better ways to prevent these adverse reactions. ..
  15. Proactive Cessation Intervention with Biomarker Feedback
    JENNIFER MC CLURE; Fiscal Year: 2008
    ..If effective, this treatment strategy could have broad potential as a public health intervention. ..
  16. CTLA-4 Inhibition and Autoimmunity in Melanoma
    Jeffrey Weber; Fiscal Year: 2008
    ..abstract_text> ..
  17. Modulation of Iron Deposition in SCD and Other Hemoglobinopathies
    ELLIOTT P contact VICHINSKY; Fiscal Year: 2010
    ....
  18. Treatment decision making in older adults newly diagnosed with multiple myeloma
    Joseph D Tariman; Fiscal Year: 2010
    ..Due to the limited studies in older adults with cancer, these specific aspects of decision-making have not been previously explored. ..
  19. Catheter Dwell Time and Risk of Bloodstream Infections in Hospitalized Neonates
    Aaron M Milstone; Fiscal Year: 2011
    ..This project will help to develop evidence-based strategies to prevent bloodstream infections among vulnerable infants hospitalized in the neonatal intensive care unit. ..
  20. IL-12 as an Adjuvant for a Melanoma Peptide Vaccine
    Jeffrey Weber; Fiscal Year: 2003
    ..The results of those assays will be used to design randomized phase III trials for resected high risk melanoma and to develop strategies for overcoming antigen-specific unresponsiveness in melanoma patients. ..
  21. PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
    JAMES LEEDER; Fiscal Year: 2003
    ..It is anticipated that the basic experimental paradigm employed for these studies can also be applied to other idiosyncratic toxicities with suspected drug bioactivation and immune etiologies. ..
  22. IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA
    Jeffrey Weber; Fiscal Year: 2003
    ....
  23. CBL FUNCTION IN CELLULAR SIGNALING AND TRANSFORMATION
    Brian Druker; Fiscal Year: 2003
    ..Through these studies the investigators should gain a greater understanding of the contribution of tyrosine phosphorylation of Cbl to its function and the role of Cbl in myeloid transformation. ..
  24. PREVENTIVE ONCOLOGY AWARD--SMOKING CESSATION AND WOMEN
    JENNIFER MC CLURE; Fiscal Year: 2003
    ..Such knowledge is important as it may lead to the development of more targeted, and therefore potentially more effective, cessation interventions. ..
  25. Therapeutic immune mechanisms of anti-CD11a in psoriasis
    James Krueger; Fiscal Year: 2004
    ..Following anti-CD1la we will look for reductions in 1) disease-associated T-cell activation, 2) Type 1 T-cells, and 3) abundance of specific, antigen-reactive T-cells in the peripheral circulation. ..
  26. HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA
    Jeffrey Weber; Fiscal Year: 2003
    ..To insure that spontaneous regression does not account for a portion of the responses, baseline measurements will be followed one month later by a second set of assessments prior to the start of the vaccine. ..
  27. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  28. CHRONIC MYELOGENOUS LEUKEMIA AND BCR-ABL SUBSTRATES
    Brian Druker; Fiscal Year: 2009
    ..Combined, these data should offer significant insights into the biology of and the mechanism of transformation by Bcr-Abl. ..
  29. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  30. Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
    JAMES LEEDER; Fiscal Year: 2007
    ..abstract_text> ..
  31. Cancer and Kinases
    Brian Druker; Fiscal Year: 2005
    ..By facilitating the development of these drugs, we hope to improve the outcome for patients with cancer as rapidly as possible. ..
  32. Eighth Cooley's Anemia Symposium
    Elliott Vichinsky; Fiscal Year: 2005
    ....
  33. SPECIAL POPULATIONS NETWORK FOR CANCER CONTROL
    Edith Mitchell; Fiscal Year: 2003
    ..abstract_text> ..
  34. LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
    Nunzio Pomara; Fiscal Year: 2005
    ..index of brain white matter organization) contribute most strongly to the acute effects of lorazepam on cognitive/motor performance or postural sway in elderly individuals receiving long-term lorazepam treatment for GAD? ..
  35. Therapeutic immune mechanisms of daclizumab in psoriasis
    James Krueger; Fiscal Year: 2004
    ..We will also measure the impact of daclizumab on T cell activation/deviation towards Type 2 T cells by sensitive flow cytometry based assays. ..
  36. Phase III Trial of Minocycline in ALS:I-Clinical Center
    Paul Gordon; Fiscal Year: 2007
    ..P.I. Dr. Robert Miller). ..
  37. Myostatin in Muscle Growth and Regeneration
    Kathryn Wagner; Fiscal Year: 2005
    ..In addition to the ultimate goal of providing clinical applications for muscle disease, this multidisciplinary approach should provide excellent training for a career integrating clinical myology and molecular neuroscience. ..
  38. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2002
    ..In summary, if this study is successful, it will change the approach to Hb E/B worldwide and result in improved quality of life and decreased mortality. (End of Abstract) ..